晚期乳膜黑色素瘤患者的免疫疗法反应和耐药性:一项回顾性队列研究
Alexander Maurer1, Giulio Clerici2, Jan A Schaab1
1Department of Nuclear Medicine, University Hospital of Zurich, University of Zurich, Zurich, Switzerland.
Clinical and experimental medicine
|October 1, 2024
概括
免疫疗法,包括ipilimumab/nivolumab和tebentafusp,显示出对转移性乳膜黑色素瘤 (mUM) 的承诺. 放射性反应模式与改善的生存率相关,但需要进一步的研究,以更好地分层患者并了解耐药机制.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 放射学 放射学是一门学科.
背景情况:
- 转移性阴道黑色素瘤 (mUM) 的预后不好.
- ipilimumab/nivolumab 和 tebentafusp 是一种免疫疗法,在mUM中显示出有效性.
- 放射性评估对于评估治疗反应至关重要.
研究的目的:
- 描述mUM患者用伊皮利穆马布/尼沃卢马布或tebentafusp.usp.治疗的放射性反应模式.
- 为了将放射性反应与无进展生存率 (PFS) 和整体生存率 (OS) 相关联.
- 评估活检中的肝脏特异性反应和病理发现.
主要方法:
- 在2018年7月至2022年12月期间接受治疗的mUM患者的回顾性分析.
- 使用RECISTv1.1和/或imPERCIST5标准进行放射性评估.
- 评估PFS,OS,肝脏反应和病理数据.
主要成果:
- 伊皮利穆马布/尼沃卢马布和特本塔福斯普都显示了更长的PFS和OS的趋势,具有完全/部分代谢或部分放射性反应.
- 整体治疗反应与两种疗法肝部位放射反应相关.
- 在肝活检中观察到病理和放射反应的差异.
结论:
- 放射性反应评估工具 (RECISTv1.1,imPERCIST5) 是有价值的,但也有局限性.
- 需要准确的生物标志物来根据疾病进展风险对mUM患者进行分层.
- 需要进一步进行翻译研究,以调查mUM的免疫疗法反应和耐药性机制.
相关概念视频
Tumor Immunotherapy
489
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
489
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cytotoxic T Cells-mediated Immune Response
857
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
857
Skin Cancer
4.0K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.0K


